Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Balacing cancer risk with progesterone therapy
EF 2024-25
Résumé
Endometrial cancer (EC) is a growing concern, being the sixth most common cancer in women worldwide. The balance of estrogen and progesterone is key to maintaining a healthy endometrium. Progesterone counteracts estrogen effects, preventing abnormal thickening of the uterine lining, known as endometrial hyperplasia (EH). EH is a risk factor for EC but can be treated with progestogens. However, while progestogens can reduce EC risk, they may increase the risk of breast cancer (BC). Studies have shown conflicting results regarding progestogen-only therapies and BC risk; study results are inconsistent and limited by small sample sizes and a narrow focus on specific progestogens. The way progestogens are delivered also matters;evidence suggests intrauterine devices (IUDs) may be safer due to lower circulating hormone levels. This study aims to examine both EC and BC risks linked to hormonal therapies, comparing oral progestins, IUDs, and other methods to women not using hormones. By analyzing health and cancer data from women aged 35 and older in British Columbia and Alberta, the research will explore how different types of progestins and delivery methods affect cancer risks. The study will calculate the rates of BC and EC and assess whether IUDs, which deliver lower doses of hormones to the body, can effectively prevent EC while minimizing BC risk. The findings will provide a clearer understanding of the safest options for hormonal therapies and contribute to future research on improving women health and cancer prevention strategies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529986
Name
Woodside Tessa
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Balacing cancer risk with progesterone therapy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Endometrial Cancer; Endometrial Hyperplasia; Estrogen; Hormone Therapy; Intra-Uterine Device; Progestogen
Abstract
Endometrial cancer (EC) is a growing concern, being the sixth most common cancer in women worldwide. The balance of estrogen and progesterone is key to maintaining a healthy endometrium. Progesterone counteracts estrogen effects, preventing abnormal thickening of the uterine lining, known as endometrial hyperplasia (EH). EH is a risk factor for EC but can be treated with progestogens. However, while progestogens can reduce EC risk, they may increase the risk of breast cancer (BC). Studies have shown conflicting results regarding progestogen-only therapies and BC risk; study results are inconsistent and limited by small sample sizes and a narrow focus on specific progestogens. The way progestogens are delivered also matters;evidence suggests intrauterine devices (IUDs) may be safer due to lower circulating hormone levels. This study aims to examine both EC and BC risks linked to hormonal therapies, comparing oral progestins, IUDs, and other methods to women not using hormones. By analyzing health and cancer data from women aged 35 and older in British Columbia and Alberta, the research will explore how different types of progestins and delivery methods affect cancer risks. The study will calculate the rates of BC and EC and assess whether IUDs, which deliver lower doses of hormones to the body, can effectively prevent EC while minimizing BC risk. The findings will provide a clearer understanding of the safest options for hormonal therapies and contribute to future research on improving women health and cancer prevention strategies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Woodside, Tessa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~